Open AccessMolecular and immunological rationale for the use of tyrosine kinase inhibitors and immune checkpoint inhibitors in glioblastomas
Publication year - 2019
Publication title -
journal of molecular and clinical medicine
Language(s) - English
Resource type - Journals
eISSN - 2617-5282
pISSN - 2616-3632
DOI - 10.31083/j.jmcm.2019.04.4201
Subject(s) - cancer research , tumor microenvironment , immune system , stromal cell , bevacizumab , tyrosine kinase , medicine , receptor tyrosine kinase , epidermal growth factor receptor , growth factor receptor , biology , cancer , immunology , chemotherapy , receptor